Kymera Therapeutics (NASDAQ: KYMR) names Terence Rooney as new CMO
Rhea-AI Filing Summary
Kymera Therapeutics, Inc. announced a leadership transition in its Chief Medical Officer role. Jared Gollob, M.D., submitted his resignation as CMO on July 27, 2026, citing personal reasons and indicating it was not due to any disagreement with the company’s practices or policies. He will continue serving as an advisor through December 31, 2026.
Effective July 27, 2026, Terence Rooney, M.D., a veteran immunology drug development leader with experience at Johnson & Johnson, Eli Lilly and Roche, becomes CMO and will lead global clinical development strategy for Kymera’s oral immunology portfolio. The company furnished a press release as Exhibit 99.1 describing his background and Dr. Gollob’s eight years of leadership.
Positive
- None.
Negative
- None.
Filing Explained
The July 27 Form 8-K furnishes the leadership announcement under Item 7.01 rather than filing it for Section 18 liability, and says it is not incorporated by reference into other filings unless specifically referenced.
8-K Event Classification
Key Figures
Key Terms
Chief Medical Officer financial
clinical-stage biopharmaceutical company financial
targeted protein degradation medical
oral small molecule degrader medicines medical
immunological diseases medical
immuno-inflammatory diseases medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What executive leadership change did Kymera Therapeutics (KYMR) report?
Who is the new Chief Medical Officer of Kymera Therapeutics (KYMR)?
Why did Jared Gollob resign as CMO of Kymera Therapeutics (KYMR)?
How long will Jared Gollob remain involved with Kymera Therapeutics (KYMR)?
What experience does Terence Rooney bring to Kymera Therapeutics (KYMR)?
What information did Kymera Therapeutics (KYMR) include in its CMO announcement exhibit?
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
(Address of principal executive offices, including zip code)
(Registrant’s telephone number, including area code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trade Symbol(s) |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.02. | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers |
Jared Gollob, M.D., communicated his intention to retire from his role as Chief Medical Officer (“CMO”) of Kymera Therapeutics, Inc. (the “Company”) and submitted his resignation on July 27, 2026. Dr. Gollob will continue providing services to the Company as an advisor until December 31, 2026. Dr. Gollob informed the Company that he resigned as CMO for personal reasons, and not as the result of any disagreement with the Company’s practices or policies.
Effective July 27, 2026, Terence Rooney, M.D., will succeed Dr. Gollob as CMO of the Company.
| Item 7.01. | Regulation FD Disclosure |
On July 27, 2026, the Company issued a press release announcing the appointment of Dr. Rooney as CMO and the retirement of Dr. Gollob. A copy of this press release is furnished as Exhibit 99.1 to this Report on Form 8-K.
The information in this Item 7.01 and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
| Item 9.01. | Exhibits |
(d) Exhibits
| Exhibit No. |
Description | |
| 99.1 | Press Release issued by Kymera Therapeutics, Inc. dated July 27, 2026. | |
| 104 | Cover Page Interactive Data | |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Kymera Therapeutics, Inc. | ||||||
| Date: July 27, 2026 | By: | /s/ Nello Mainolfi | ||||
| Nello Mainolfi, Ph.D. | ||||||
| President and Chief Executive Officer | ||||||
Exhibit 99.1
Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer
Dr. Rooney, former immunology leader at Johnson & Johnson, will lead clinical development strategy across Kymera’s industry-leading oral immunology portfolio
Jared Gollob, MD, will retire from his role after eight years of leadership at the Company
Watertown, Mass. (July 27, 2026) – Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the appointment of Terence Rooney, MD, as Chief Medical Officer. Dr. Rooney is an accomplished drug development leader with extensive experience advancing immunology therapies across the full development lifecycle, from early clinical stages through commercialization and franchise expansion, helping bring important new medicines to patients around the world. In his role, Dr. Rooney will lead Kymera’s global clinical development strategy and guide the advancement of the Company’s oral immunology portfolio across multiple immuno-inflammatory diseases. He succeeds Jared Gollob, MD, who will retire from his role after eight years with the Company and will remain as an advisor through the end of the year.
“We are thrilled to welcome Terence at a time of tremendous momentum and opportunity for our company, with multiple clinical programs advancing and an early innovation engine rooted in bold science and the needs of patients. Terence’s broad development experience, physician-scientist perspective and proven leadership in delivering important immunology medicines to patients at a global scale make him uniquely suited to help us realize the full potential of our pipeline and guide us through this next stage of growth,” said Nello Mainolfi, PhD, Founder, President and CEO, Kymera Therapeutics. “I also want to thank Jared for his extraordinary leadership and partnership. From Kymera’s earliest days, Jared has helped shape not only our development strategy and infrastructure, but also the company we are today, and we are deeply grateful for his significant contributions and unwavering commitment to changing patients’ lives.”
“Having spent most of my career in immunology, I have seen firsthand the significant treatment gaps that remain for patients living with these chronic conditions and the importance of advancing science that can truly shift the status quo and evolve care,” said Dr. Rooney. “Kymera stands out for the depth of its science, the execution across its diverse portfolio, and the opportunity to build on this momentum to expand oral treatment options for multiple diseases. I am excited to join the Kymera team at this critical time and advance the Company’s work to improve outcomes for patients around the world.”
Prior to joining Kymera, Dr. Rooney served as Senior Vice President, Portfolio and Asset Management Leader, Immunology, at Johnson & Johnson, where he led global compound development teams and portfolio strategy and operations across immunology. Earlier in his career, he held senior leadership roles across immunology R&D at Eli Lilly and Roche, including work at the interface of discovery, translational medicine and clinical development. Across his career, his work has spanned small molecules, peptides, biologics and cell therapies, combination and precision therapy strategies, and therapeutic areas including dermatology, respiratory, rheumatology, gastroenterology and rare diseases. Dr. Rooney has contributed to successful marketing applications for groundbreaking medicines including ICOTYDE®, IMAAVY®, OLUMIANT®, STELARA®, and TREMFYA®.
Dr. Rooney received his medical degrees from the Royal College of Surgeons in Ireland. He completed his training in internal medicine at the Dublin Academic Teaching Hospitals in Ireland, and rheumatology fellowships both there and at the University of California, San Francisco. He received a doctorate from the National University of Ireland and has authored some 50 peer-reviewed scientific publications.
About Kymera Therapeutics
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X or LinkedIn.
Investor Contact:
Justine Koenigsberg
investors@kymeratx.com
857-285-5300
Media Contact:
Matthew Henson
media@kymeratx.com
857-285-5300